TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 174 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,045,347 | -22.5% | 228,786 | +33.1% | 0.04% | -25.0% |
Q2 2023 | $2,639,555 | -11.5% | 171,846 | +29.6% | 0.05% | -13.3% |
Q1 2023 | $2,982,804 | +410.7% | 132,628 | +377.5% | 0.06% | +445.5% |
Q4 2022 | $584,066 | -69.1% | 27,773 | -63.7% | 0.01% | -78.0% |
Q3 2022 | $1,888,000 | – | 76,604 | – | 0.05% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |